Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -131.42% is 39% above its 5-year average of -216.06%, near the high end of its 5-year range (-374.94%–-101.24%).
6.27% above its 12-month average of -140.22%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -144.62%.
EBITDA MARGIN
-131.42%
EBITDA MARGIN AVG TTM
-140.22%
EBITDA MARGIN AVG 3Y
-162.42%
EBITDA MARGIN AVG 5Y
-216.06%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+6.27%
CURRENT VS 3Y AVG
+19.09%
CURRENT VS 5Y AVG
+39.17%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Rapid Micro Biosystems, Inc.
Market Cap
$44.40M
EBITDA Margin
-131.42%
TTM Avg
-140.22%
3Y Avg
-162.42%
5Y Avg
-216.06%
Market Cap
$43.31M
EBITDA Margin
-0.99%
TTM Avg
4.72%
3Y Avg
-25.09%
5Y Avg
-32.37%
Market Cap
$43.66M
EBITDA Margin
-376.33%
TTM Avg
-387.64%
3Y Avg
-608.18%
5Y Avg
-1395.53%
Market Cap
$44.27M
EBITDA Margin
-89.16%
TTM Avg
-101.97%
3Y Avg
-124.94%
5Y Avg
-147.77%
Market Cap
$44.24M
EBITDA Margin
-148.02%
TTM Avg
-167.05%
3Y Avg
-193.51%
5Y Avg
-252.90%
Market Cap
$44.54M
EBITDA Margin
14.14%
TTM Avg
17.13%
3Y Avg
-2.79%
5Y Avg
-117.76%
Market Cap
$44.98M
EBITDA Margin
-3807.96%
TTM Avg
-2001.11%
3Y Avg
-1442.90%
5Y Avg
-1442.90%
Market Cap
$41.33M
EBITDA Margin
-217.02%
TTM Avg
-395.41%
3Y Avg
-245.06%
5Y Avg
-171.96%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Rapid Micro Biosystems, Inc. (RPID) | $44.40M | -131.42% | -140.22% | -162.42% | -216.06% |
| BioStem Technologies, Inc. (BSEM)vs › | $43.31M | -0.99% | 4.72% | -25.09% | -32.37% |
| Nano-X Imaging Ltd. (NNOX)vs › | $43.66M | -376.33% | -387.64% | -608.18% | -1395.53% |
| CVRx, Inc. (CVRX)vs › | $44.27M | -89.16% | -101.97% | -124.94% | -147.77% |
| DarioHealth Corp. (DRIO)vs › | $44.24M | -148.02% | -167.05% | -193.51% | -252.90% |
| SANUWAVE Health Inc. (SNWV)vs › | $44.54M | 14.14% | 17.13% | -2.79% | -117.76% |
| Werewolf Therapeutics, Inc. (HOWL)vs › | $44.98M | -3807.96% | -2001.11% | -1442.90% | -1442.90% |
| Precipio, Inc. (PRPO)vs › | $41.76M | 2.29% | -7.32% | -44.00% | -66.61% |
| Veru Inc. (VERU)vs › | $41.33M | -217.02% | -395.41% | -245.06% | -171.96% |
| Instil Bio, Inc. (TIL)vs › | $46.76M | -24194.20% | -24194.20% | -24194.20% | -24194.20% |
Gross Margin
22.6%
EBITDA Margin
-131.4%
Operating Margin
-141.4%
Net Margin
-145.6%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -144.62% |
| 2026-03-31 | -164.28% |
| 2025-12-31 | -101.24% |
| 2025-09-30 | -134.83% |
| 2025-06-30 | -156.11% |
| 2025-03-31 | -150.09% |
| 2024-12-31 | -113.90% |
| 2024-09-30 | -148.74% |
| 2024-06-30 | -189.63% |
| 2024-03-31 | -241.79% |
| 2023-12-31 | -179.80% |
| 2023-09-30 | -224.05% |
| 2023-06-30 | -285.55% |
| 2023-03-31 | -280.30% |
| 2022-12-31 | -374.94% |
| 2022-09-30 | -340.83% |
| 2022-06-30 | -346.92% |
| 2022-03-31 | -347.09% |
| 2021-12-31 | -270.85% |
| 2021-09-30 | -170.17% |
| 2021-06-30 | -171.45% |
| 2021-03-31 | -187.13% |
| 2020-12-31 | -179.38% |
| 2020-09-30 | -138.06% |
| 2020-06-30 | -217.08% |
| 2020-03-31 | -225.48% |
